A 62-year-old woman with extensive-stage small cell lung cancer has completed 4 cycles of cisplatin + etoposide with a partial response. She is now in remission and clinically stable. Which agent is the drug of choice for maintenance therapy to prolong overall survival?

Question

Accepted Answer

B. Atezolizumab. ## Maintenance Immunotherapy in Extensive-Stage SCLC

**Key Point:** Atezolizumab (PD-L1 inhibitor) is the only FDA-approved and guideline-recommended maintenance agent for extensive-stage SCLC after chemotherapy response, based on the IMpower133 trial.

### IMpower133 Trial (Landmark Evidence)

**Study Design:**
- Extensive-stage SCLC patients with response/stable disease after 4 cycles of cisplatin + etoposide
- Randomized to: Atezolizumab vs. placebo (maintenance)

**Results:**
- **Median OS:** 12.3 months (atezolizumab) vs. 10.3 months (placebo) → **2-month OS benefit**
- **Median PFS:** 5.2 months vs. 4.3 months
- **Grade ≥3 adverse events:** 18% (atezolizumab) vs. 3% (placebo) — manageable with monitoring

**High-Yield:** Atezolizumab is the ONLY agent with level 1A evidence for maintenance in extensive-stage SCLC. This is a frequently tested fact.

### Mechanism: Why Immunotherapy Works in SCLC

```mermaid
flowchart TD
  A[SCLC tumor cells]:::outcome --> B[High PD-L1 expression]:::outcome
  B --> C[Exhausted T cells cannot attack]:::outcome
  D[Atezolizumab blocks PD-L1]:::action --> E[Restores T-cell immunity]:::action
  E --> F[Tumor cell apoptosis]:::outcome
  style A fill:#e8f4f8
  style B fill:#e8f4f8
  style C fill:#ffe8e8
  style D fill:#e8f8e8
  style E fill:#e8f8e8
  style F fill:#e8f4f8
```

### Comparison of Maintenance Options in SCLC

| Agent | Class | Evidence in SCLC | Status |
|-------|-------|------------------|--------|
| **Atezolizumab** | PD-L1 inhibitor | IMpower133 (OS +2 mo) | **FDA approved, guideline standard** |
| **Nivolumab** | PD-1 inhibitor | CheckMate 331 (negative) | Not recommended |
| **Bevacizumab** | Anti-VEGF | No SCLC data | Not indicated |
| **Erlotinib** | EGFR TKI | No benefit in EGFR WT SCLC | Not indicated |

**Clinical Pearl:** CheckMate 331 tested nivolumab (PD-1 inhibitor) as maintenance in extensive-stage SCLC and failed to show OS benefit, making atezolizumab (PD-L1 inhibitor) the preferred checkpoint inhibitor.

**Warning:** Do not confuse atezolizumab with nivolumab — both are checkpoint inhibitors, but only atezolizumab has proven maintenance benefit in SCLC. Nivolumab failed in CheckMate 331.

### Dosing & Administration
- Atezolizumab 1200 mg IV every 3 weeks
- Continued until disease progression or unacceptable toxicity
- Monitor for immune-related adverse events (irAEs): pneumonitis, hepatitis, colitis

**Mnemonic:** **ATEZ** = **A**fter **T**reatment with **E**toposide/**Z**isplatin (maintenance in SCLC)

[cite:Harrison 21e Ch 105; IMpower133 Trial, Lancet 2019]

Answer

A. Bevacizumab

Answer

C. Erlotinib

Answer

D. Nivolumab

A 62-year-old woman with extensive-stage small cell lung cancer has completed 4 cycles of cisplatin + etoposide with a partial response. She is now in remission and clinically stable. Which agent is the drug of choice for maintenance therapy to prolong overall survival?

Explanation

Maintenance Immunotherapy in Extensive-Stage SCLC

IMpower133 Trial (Landmark Evidence)

Mechanism: Why Immunotherapy Works in SCLC

Comparison of Maintenance Options in SCLC

Dosing & Administration

Practice similar questions

Join our NEET PG community

Agent	Class	Evidence in SCLC	Status
Atezolizumab	PD-L1 inhibitor	IMpower133 (OS +2 mo)	FDA approved, guideline standard
Nivolumab	PD-1 inhibitor	CheckMate 331 (negative)	Not recommended
Bevacizumab	Anti-VEGF	No SCLC data	Not indicated
Erlotinib	EGFR TKI	No benefit in EGFR WT SCLC	Not indicated